AB027. Distinguishing oligodendroglioma from astrocytoma: a radiological case report.

IF 2.1 4区 医学 Q3 ONCOLOGY Chinese clinical oncology Pub Date : 2024-08-01 DOI:10.21037/cco-24-ab027
Annisa Poppy Zolanda, Reyhan Eddy Yunus
{"title":"AB027. Distinguishing oligodendroglioma from astrocytoma: a radiological case report.","authors":"Annisa Poppy Zolanda, Reyhan Eddy Yunus","doi":"10.21037/cco-24-ab027","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Oligodendroglioma, the third most common glioma, accounts for 5% of primary brain tumors and around 20% of all glial neoplasms. It is a rare brain tumor that develops from glial cells called oligodendrocytes, which cover nerve cells. Oligodendroglioma is classified as an adult diffuse glioma in the fifth edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS). Patients may present with cognitive impairment, aphasia, behavioral changes, and seizures. The symptoms at presentation are often related to the anatomic location of the tumor.</p><p><strong>Case description: </strong>A 55-year-old female presented with episodes of facial seizure with drooping on the right side of her face 4 months before coming to our hospital. Her seizures lasted around one minute, causing her to be unable to speak during the seizure. She also complained of chronic headaches in the last 1 year. She initially underwent a non-contrast computed tomography (CT) scan of the brain. The scans showed an isodense calcified mass on the perifalcine anterior left lobe with surrounding peritumoral edema. Magnetic resonance imaging (MRI) brain confirmed the presence of an intraaxial white matter mass involving the left frontal lobe. This tumor did not demonstrate any contrast enhancement. MRI findings were suggestive of a low-grade astrocytoma. Histopathological examination following craniotomy and tumor removal surgery confirmed the diagnosis of oligodendroglioma not otherwise specified (NOS) CNS WHO grade II. Molecular analysis revealed to be isocitrate dehydrogenase (IDH) wildtype, inconsistent with the classic molecular profile of oligodendroglioma. The patient underwent adjuvant radiotherapy following surgery. Subsequent follow-up assessments demonstrated stable disease with improvement in symptoms.</p><p><strong>Conclusions: </strong>Differentiating between oligodendroglioma and astrocytoma poses a significant challenge due to their overlapping clinical and radiological features, yet understanding their key differences is crucial for accurate diagnosis. On MRI, calcification strongly favors oligodendrogliomas, while T2/fluid-attenuated inversion recovery (FLAIR) mismatch sign favors astrocytoma. Only 50% of oligodendrogliomas appear to be contrast-enhanced. While oligodendrogliomas and astrocytomas share some similarities, careful consideration is essential for accurate differentiation, even though histopathological and molecular findings are the final determinants of diagnosis.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 Suppl 1","pages":"AB027"},"PeriodicalIF":2.1000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/cco-24-ab027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Oligodendroglioma, the third most common glioma, accounts for 5% of primary brain tumors and around 20% of all glial neoplasms. It is a rare brain tumor that develops from glial cells called oligodendrocytes, which cover nerve cells. Oligodendroglioma is classified as an adult diffuse glioma in the fifth edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS). Patients may present with cognitive impairment, aphasia, behavioral changes, and seizures. The symptoms at presentation are often related to the anatomic location of the tumor.

Case description: A 55-year-old female presented with episodes of facial seizure with drooping on the right side of her face 4 months before coming to our hospital. Her seizures lasted around one minute, causing her to be unable to speak during the seizure. She also complained of chronic headaches in the last 1 year. She initially underwent a non-contrast computed tomography (CT) scan of the brain. The scans showed an isodense calcified mass on the perifalcine anterior left lobe with surrounding peritumoral edema. Magnetic resonance imaging (MRI) brain confirmed the presence of an intraaxial white matter mass involving the left frontal lobe. This tumor did not demonstrate any contrast enhancement. MRI findings were suggestive of a low-grade astrocytoma. Histopathological examination following craniotomy and tumor removal surgery confirmed the diagnosis of oligodendroglioma not otherwise specified (NOS) CNS WHO grade II. Molecular analysis revealed to be isocitrate dehydrogenase (IDH) wildtype, inconsistent with the classic molecular profile of oligodendroglioma. The patient underwent adjuvant radiotherapy following surgery. Subsequent follow-up assessments demonstrated stable disease with improvement in symptoms.

Conclusions: Differentiating between oligodendroglioma and astrocytoma poses a significant challenge due to their overlapping clinical and radiological features, yet understanding their key differences is crucial for accurate diagnosis. On MRI, calcification strongly favors oligodendrogliomas, while T2/fluid-attenuated inversion recovery (FLAIR) mismatch sign favors astrocytoma. Only 50% of oligodendrogliomas appear to be contrast-enhanced. While oligodendrogliomas and astrocytomas share some similarities, careful consideration is essential for accurate differentiation, even though histopathological and molecular findings are the final determinants of diagnosis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
AB027.少突胶质细胞瘤与星形细胞瘤的鉴别:放射学病例报告。
背景:少突胶质细胞瘤是第三大常见胶质瘤,占原发性脑肿瘤的 5%,约占所有胶质肿瘤的 20%。它是一种罕见的脑肿瘤,由覆盖神经细胞的胶质细胞少突胶质细胞发展而成。在世界卫生组织(WHO)第五版《中枢神经系统肿瘤分类》中,少突胶质细胞瘤被归类为成人弥漫性胶质瘤。患者可能出现认知障碍、失语、行为改变和癫痫发作。发病时的症状通常与肿瘤的解剖位置有关:一名 55 岁的女性在来我院就诊前 4 个月出现面部癫痫发作,右侧面部下垂。发作持续约一分钟,发作时无法说话。在过去的一年里,她还抱怨自己长期头痛。她最初接受了脑部非对比计算机断层扫描(CT)。扫描结果显示,左脑前叶周围有一等密度钙化肿块,肿块周围有水肿。脑部磁共振成像(MRI)证实左额叶存在轴内白质肿块。该肿瘤未显示任何对比度增强。核磁共振成像结果提示为低级别星形细胞瘤。开颅手术和肿瘤切除术后的组织病理学检查证实了少突胶质细胞瘤的诊断,未另作说明(NOS),中枢神经系统 WHO II 级。分子分析显示患者为异柠檬酸脱氢酶(IDH)野生型,与少突胶质细胞瘤的典型分子特征不符。患者在手术后接受了辅助放疗。随后的随访评估显示病情稳定,症状有所改善:由于少突胶质细胞瘤和星形细胞瘤的临床和放射学特征相互重叠,因此它们之间的鉴别是一项重大挑战,但了解它们的主要区别对于准确诊断至关重要。在磁共振成像中,钙化更倾向于少突胶质细胞瘤,而T2/流体增强反转恢复(FLAIR)错配征更倾向于星形细胞瘤。只有50%的少突胶质细胞瘤出现对比增强。虽然少突胶质细胞瘤和星形细胞瘤有一些相似之处,但要准确鉴别,必须仔细考虑,尽管组织病理学和分子检查结果是诊断的最终决定因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.90
自引率
0.00%
发文量
0
期刊介绍: The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO) publishes articles that describe new findings in the field of oncology, and provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to: multimodality therapy, biomarkers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field. To that end, Chin Clin Oncol is dedicated to translating the latest research developments into best multimodality practice. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of cancer subjects.
期刊最新文献
Intriguing future: single-site robotic-assisted radical prostatectomy. A periungual eccrine poroma masquerading as amelanotic melanoma: a case report. Immunotherapy resistance in colorectal cancer with liver metastases: challenges & therapeutic advances. Artificial intelligence assistance during upper endoscopy: a game changer in detection of esophageal squamous cell carcinoma? Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1